RecruitingNCT06075433

Efficacy and Safety of 1-year Duration of DAPT After GENOSS® DES Implantation in Patients with Coronary Artery Disease According to the Complex Higher-risk Procedure

A Prospective, Multicenter, Observational Study to Evaluate the Efficacy and Safety of 1 Year Duration of DAPT After GENOSS® DES Implantation in Patients with Coronary Artery Disease According to the Complex Higher-Risk Procedure


Sponsor

Genoss Co., Ltd.

Enrollment

1,000 participants

Start Date

May 13, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

The objective of study is to evaluate the efficacy and safety of 1 year duration of DAPT after GENOSS® DES Implantation in patients with coronary artery disease according to the complex higher-risk (and indicated) procedure.


Eligibility

Min Age: 19 Years

Inclusion Criteria3

  • Patients of 19 and over
  • Patients with coronary artery disease treated with GENOSS SES
  • Participants who voluntarily decide to participate in this clinical trial, agree to the study protocol and clinical follow-up plan, and provide written informed consent as study participants

Exclusion Criteria5

  • Patients with cardiogenic shock at the time of hospitalization
  • Patients who are pregnant or planning to become pregnant
  • Patients with a life expectancy of less than 1 year
  • Patients participating in randomized controlled trials using other medical devices
  • Patients who have already received treatment with another DES (Drug Eluting Stent) or BMS (Bare Metal Stent) at the time of registration (However, other stent insertions are allowed due to failure of GENOSS DES insertion)

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Wonju Severance Christian Hospital

Wŏnju, Gangwon State, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06075433


Related Trials